Soliqua 100/33 (insulin glargine/lixisenatide)

Sanofi U.S.

Soliqua 100/33 combines long-acting insulin glargine with the GLP-1 receptor agonist lixisenatide. The insulin helps glucose enter the cells to be used as fuel. The GLP-1 receptor agonist helps release insulin when blood glucose is high and lower the amount of glucose produced by the liver. This drug is not recommended for use in conjunction with additional bolus (mealtime) insulin therapy. Medications in the GLP-1 receptor agonist class may offer heart and kidney benefits for people with cardiovascular disease. Talk to your doctor about your options and whether switching to one of these drugs may help you. Because type 2 diabetes medications act in different ways to lower blood glucose levels, providers will often prescribe multiple drugs to a patient. For example, a doctor might prescribe both a biguanide and a sulfonylurea. Several of the more popular combinations of oral drugs can be prescribed together in a single pill. Each medication has its own side effects; read labels carefully to be sure you know what they are.


Features


Specs

Generic Name:
Insulin glargine/Lixisenatide
Drug Class:
Insulin + GLP-1 receptor agonists
Cost:
High
Medication Type:
Injected